ClinicalTrials.gg
Sign In
RecruitingNCT02357238Updated Mar 4, 2026

Genetics of Uveitis

An observational study in Uveitis and Infectious Uveitis, sponsored by The Cleveland Clinic. Recruiting at 1 site in United States. Open to participants aged 6 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-04.

Sponsored by The Cleveland Clinic · Observational

From the registry’s dates

  • Started Jan 2011; still recruiting 15 years 10 months later.
Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
1,500
Ages
6 Years and older
Sex
All
01

Study summary

In order to improve the investigators knowledge about uveitis and the underlying mechanism of disease, the investigators propose collecting blood from patients with uveitis, isolating DNA and sequencing the DNA to identify genetic mutations or associations in these patients.

02

Conditions studied

  • Uveitis
  • Infectious Uveitis

Keywords

  • Uveitis
  • Infectious
03

In context

Uveitis

299 studies on the registry are indexed under Uveitis; 32 are open to participants now.

This study's planned enrollment of 1,500 is above the median of 107 across 104 observational studies indexed under Uveitis.

Browse Uveitis studies →

Lead sponsor

The Cleveland Clinic is the lead sponsor of 831 studies on the registry; 119 are open to participants now.

Of its 90 completed or terminated interventional studies of FDA-regulated products, 73 (81%) have results posted.

Browse The Cleveland Clinic studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Any patient able to sign an informed consent or child of age 6 with parental /guardian consent with the diagnosis of uveitis or infectious uveitis.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Any patient above with the diagnosis of uveitis.
  • Any patient with a diagnosis of infectious uveitis such as toxoplasmosis retinochoroiditis, herpes associated retinitis.

Exclusion criteria

Exclusion Criteria:

  • Patients who are unable to give consent
  • Patients in whom an adequated blood sample can not be obtained.
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
1,500 participants (estimated)
Target follow-up
10 Years
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • Uveitis

    Uveitis or infectious uveitis patients

06

What researchers measure

Primary outcomes

  1. Non infectious uveitis

    Distinct uveitis conditions will have a polymorphism association or specific mutation.

    Time frame: 5 years

Secondary outcomes

  1. Infectious uveitis

    Infectious uveitis (such as herpes associated uveitis, toxoplasmosis retinochoroiditis) will have specific polymorphisms/mutations in innate immune system genes which predispose the patient to infectious uveitis.

    Time frame: 5 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2011 (actual). Primary completion is estimated for Jan 2030, 228 months after the start.

Of 32 observational studies under Uveitis, half reached primary completion within 77 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 143. This study's planned 228 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 3, 2015
First posted
Feb 6, 2015
StartActual
Jan 2011
Primary completionEst.
Jan 2030
CompletionEst.
Jan 2030
Last update
Mar 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02357238
Lead sponsor
The Cleveland Clinic
Responsible party
Sunil Srivastava (Staff physician, The Cleveland Clinic) — Principal investigator
First posted
Feb 6, 2015
Start date
Jan 2011
Primary completion
Jan 2030 (estimated)
Completion
Jan 2030 (estimated)
Last update
Mar 4, 2026

Study contacts

Kimberly M Baynes, BSN, RN, COA
Contact
baynesk@ccf.org
216-444-2566
Sunil K. Srivastava, M.D.
principal investigator · The Cleveland Clinic

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Uveitis →

Other studies from this sponsor

The Cleveland Clinic →

Start the discussion